109 related articles for article (PubMed ID: 33866341)
21. The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?
Bilici A; Ustaalioglu BB; Seker M; Kefeli U; Canpolat N; Tekinsoy B; Ozugur S; Gumus M
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):64-73. PubMed ID: 20838995
[TBL] [Abstract][Full Text] [Related]
22. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
23. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer.
Jakobsen JK; Frahm Nielsen T; Ipsen P; Albrecht-Beste E; Cardoso Costa J; Alslev L; Predbjørn Krarup K; Grønkaer Toft B; Høyer S; Bouchelouche K; Bjerggaard Jensen J
BJU Int; 2021 Feb; 127(2):254-262. PubMed ID: 33448605
[TBL] [Abstract][Full Text] [Related]
24. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.
Picchio M; Mangili G; Samanes Gajate AM; De Marzi P; Spinapolice EG; Mapelli P; Giovacchini G; Sigismondi C; Viganò R; Sironi S; Messa C
Nucl Med Commun; 2010 Jun; 31(6):506-12. PubMed ID: 20168262
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of 18F-FDG PET/CT for detecting synchronous advanced colorectal neoplasia in patients with gastric cancer.
Choi BW; Kim HW; Won KS; Song BI; Cho KB; Bae SU
Medicine (Baltimore); 2016 Sep; 95(36):e4741. PubMed ID: 27603371
[TBL] [Abstract][Full Text] [Related]
26. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.
Sun L; Su XH; Guan YS; Pan WM; Luo ZM; Wei JH; Wu H
World J Gastroenterol; 2008 Aug; 14(29):4627-32. PubMed ID: 18698676
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
28. Multiple primary malignant tumors of upper gastrointestinal tract: a novel role of 18F-FDG PET/CT.
Sun L; Wan Y; Lin Q; Sun YH; Zhao L; Luo ZM; Wu H
World J Gastroenterol; 2010 Aug; 16(31):3964-9. PubMed ID: 20712059
[TBL] [Abstract][Full Text] [Related]
29. The impact of baseline
Foley KG; Coomer W; Coles B; Bradley KM
Br J Radiol; 2022 Oct; 95(1139):20220437. PubMed ID: 36129138
[TBL] [Abstract][Full Text] [Related]
30. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
31. [Clinical application of (18)F-FDG PET/CT to staging and treatment effectiveness monitoring of nasopharyngeal carcinoma].
Wang GH; Lau EW; Shakher R; Binns DS; Hogg A; Drummond E; Hicks RJ
Ai Zheng; 2007 Jun; 26(6):638-42. PubMed ID: 17562272
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
33. [18F]FDG PET/CT for assessing inguinal lymph nodes in patients with penile cancer - correlation with histopathology after inguinal lymphadenectomy.
Dräger DL; Heuschkel M; Protzel C; Erbersdobler A; Krause BJ; Hakenberg OW; Schwarzenböck SM
Nuklearmedizin; 2018 Feb; 57(1):26-30. PubMed ID: 29536497
[TBL] [Abstract][Full Text] [Related]
34. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer.
Kim SY; Roh JL; Yeo NK; Kim JS; Lee JH; Choi SH; Nam SY
Ann Oncol; 2007 Oct; 18(10):1698-703. PubMed ID: 17716985
[TBL] [Abstract][Full Text] [Related]
35. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer.
Sasaki K; Kawasaki H; Sato M; Koyama K; Yoshimi F; Nagai H
Dig Surg; 2017; 34(1):60-67. PubMed ID: 27454870
[TBL] [Abstract][Full Text] [Related]
36. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
[TBL] [Abstract][Full Text] [Related]
37. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Value of
Voskuilen CS; Schweitzer D; Jensen JB; Nielsen AM; Joniau S; Muilwijk T; Necchi A; Azizi M; Spiess PE; Briganti A; Bandini M; Goffin K; Bouchelouche K; van Werkhoven E; Shariat SF; Xylinas E; Azawi NH; Ku JH; Foerster B; van Rhijn BWG; Vegt E; Hendricksen K
Eur Urol Oncol; 2020 Feb; 3(1):73-79. PubMed ID: 31591037
[TBL] [Abstract][Full Text] [Related]
39. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
40. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
